Radiopharmaceutical hopeful Draximage is laying the groundwork for its entry into the nuclear medicine market. The Montreal company this month signed an agreement with a biotechnology firm that should enable Draximage to expand its R&D pipeline. It
Radiopharmaceutical hopeful Draximage is laying the groundwork for its entry into the nuclear medicine market. The Montreal company this month signed an agreement with a biotechnology firm that should enable Draximage to expand its R&D pipeline. It also closed the acquisition of a pharmaceutical manufacturing facility in Quebec that will become its permanent headquarters.
In the first agreement, Draximage signed a deal with Molecular Targeting Technology (MTTI) of Malvern, PA, to develop, manufacture, and market new imaging agents. The first potential product covered by the relationship is Amiscan, a formulation of technetium-99m glucarate being developed for the early diagnosis of acute myocardial infarction. Preliminary results with the agent indicate that it could be used to diagnose and localize myocardial infarct within a few hours of onset.
In the other deal, Draximage's parent company, Draxis Health, completed the acquisition from IVX BioScience of a manufacturing facility in Kirkland, Quebec, that formerly was used by pharmaceutical giant Burroughs Wellcome. The facility will become the headquarters for Draximage and will assume manufacturing responsibilities for other Draxis products. Draximage is developing a range of peptide-based targeted radiopharmaceuticals for applications such as deep vein thrombosis, oncology, and lung and kidney scans (SCAN 2/18/98).
Can CT-Based AI Provide Automated Detection of Colorectal Cancer?
February 14th 2025For the assessment of contrast-enhanced abdominopelvic CT exams, an artificial intelligence model demonstrated equivalent or better sensitivity than radiologist readers, and greater than 90 percent specificity for the diagnosis of colorectal cancer.
Key Chest CT Parameters for Body Composition May be Prognostic for Patients with Resectable NSCLC
February 11th 2025A high intermuscular adipose index has a 49 percent increased likelihood of being associated with lower overall survival in patients with resectable non-small cell lung cancer (NSCLC), according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Comparative AI Study Shows Merits of RapidAI LVO Software in Stroke Detection
February 6th 2025The Rapid LVO AI software detected 33 percent more cases of large vessel occlusion (LVO) on computed tomography angiography (CTA) than Viz LVO AI software, according to a new comparative study presented at the International Stroke Conference (ISC).
New CT Angiography Study Shows Impact of COVID-19 on Coronary Inflammation and Plaque
February 5th 2025Prior COVID-19 infection was associated with a 28 percent higher progression of total percent atheroma volume (PAV) annually and over a 5 percent higher incidence of high-risk plaque in patients with coronary artery lesions, according to CCTA findings from a new study.